Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD)

Linda P. Dwoskin, B. Matthew Joyce, Guangrong Zheng, Nichole M. Neugebauer, Vamshi K. Manda, Paul Lockman, Roger L. Papke, Michael T. Bardo, Peter A. Crooks

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Limitations in efficacy and high relapse rates of currently available smoking cessation agents reveal the need for more efficacious pharmacotherapies. One strategy is to develop subtype-selective nicotinic receptor (nAChR) antagonists that inhibit nicotine-evoked dopamine (DA) release, the primary neurotransmitter involved in nicotine reward. Simple alkylation of the pyridino N-atom converts nicotine from a potent agonist into a potent antagonist. The classical antagonists, hexamethonium and decamethonium, differentiate between peripheral nAChR subtypes. Using a similar approach, we interconnected varying quaternary ammonium moieties with a lipophilic linker to provide N,N′-bis-nicotinium analogs, affording a lead compound, N,N′-dodecyl-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), which inhibited nicotine-evoked DA release and decreased nicotine self-administration. The current work describes a novel compound, 1-(3-picolinium)-12-triethylammonium-dodecane dibromide (TMPD), a hybrid of bPiDDB and decamethonium. TMPD completely inhibited (IC50 = 500 nM) nicotine-evoked DA release from superfused rat striatal slices, suggesting that TMPD acts as a nAChR antagonist at more than one subtype. TMPD (1 μM) inhibited the response to acetylcholine at α3β4, α4β4, α4β2, and α1β1εδ receptors expressed in Xenopus oocytes. TMPD had a 2-fold higher affinity than choline for the blood-brain barrier choline transporter, suggesting brain bioavailability. TMPD did not inhibit hyperactivity in nicotine sensitized rats, but significantly and specifically decreased nicotine self-administration. Together, the results suggest that TMPD may have the ability to reduce the rewarding effect of nicotine with minimal side effects, a pharmacological profile indicative of potential clinical utility for the treatment of tobacco dependence.

Original languageEnglish
Pages (from-to)1271-1282
Number of pages12
JournalBiochemical Pharmacology
Issue number8
StatePublished - Oct 15 2007

Bibliographical note

Funding Information:
The authors acknowledge generous funding of this research from the NIH (DA017548). We also thank Emily Geary, Lisa Jacobs and Jason Ross for assistance in conducting the experiments.


  • Blood-brain barrier choline transporter
  • Dopamine
  • Nicotine
  • Nicotinic receptors
  • Smoking cessation
  • TMPD

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology


Dive into the research topics of 'Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD)'. Together they form a unique fingerprint.

Cite this